Request for Proposals: Pfizer Research and Quality Improvement Grant (Italy)

Deadline: 27-Mar-2026

Pfizer is offering competitive grants of up to €50,000 for one-year projects that improve care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors. Eligible projects may focus on quality improvement, personalized treatment strategies, patient-centered care, and research targeting older adults, comorbidities, or specific tumor characteristics. The funding is open to Italian organizations with qualified investigators.

Overview of the Grant Program

Pfizer’s funding initiative aims to support quality improvement and research projects that enhance care for patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors. The program targets projects that establish, investigate, or implement strategies to improve clinical outcomes, patient experience, and quality of life. The initiative recognizes that advances in treatment have extended survival, creating a need to adapt care models to evolving patient needs.

Key Focus Areas

The grant supports projects addressing the following:

• Quality improvement initiatives or research projects that enhance care delivery

• Personalized monitoring and treatment strategies for HR+/HER2- metastatic breast cancer

• Measurable improvements in quality of care

• First-line treatment with CDK4/6 inhibitors

• Special attention to vulnerable populations, including patients aged 65+, patients with comorbidities, polypharmacy, frailty, or specific tumor characteristics

• Integration of psychosocial considerations into care

• Prioritization of patient quality of life and subjective assessments of treatment impact using validated tools

Eligibility Criteria

Eligible applicants must meet the following conditions:

• Organizations based in Italy capable of directly receiving funding

• Projects led by qualified principal investigators affiliated with the funding institution

• Interdepartmental or interinstitutional collaborations are encouraged when roles are clearly defined

Grant Details

• Funding amount: Up to €50,000 per project

• Project duration: Maximum one year

• Eligible projects: Must address care improvement, research, or implementation strategies for HR+/HER2- metastatic breast cancer

Why This Grant Matters

The introduction of CDK4/6 inhibitors in combination with endocrine therapy has transformed the therapeutic landscape for HR+/HER2- metastatic breast cancer. Patients are increasingly managed as chronic disease cases, requiring care pathways that consider medical, psychosocial, and quality-of-life factors. This grant encourages initiatives that address these evolving clinical and supportive needs, improving patient outcomes and experience.

How to Apply

1. Define your project: Identify an initiative that addresses quality improvement, personalized care, or research gaps in HR+/HER2- metastatic breast cancer.

2. Confirm eligibility: Ensure your organization and principal investigator meet the criteria.

3. Prepare project details: Include objectives, methods, expected outcomes, patient populations, and measurable indicators of success.

4. Budget planning: Clearly outline expenses within the €50,000 maximum funding limit.

5. Collaborations (if applicable): Define roles and responsibilities for all participating departments or institutions.

6. Submit application: Follow Pfizer’s submission guidelines for Italian institutions.

Common Tips and Pitfalls

• Ensure the project is patient-centered and addresses measurable improvements in care.

• Target populations with specific clinical or psychosocial needs for higher relevance.

• Clearly justify the budget and project duration.

• Include validated tools for assessing patient-reported outcomes where possible.

• Avoid vague or overly broad proposals lacking measurable impact.

Frequently Asked Questions (FAQ)

1. Who can apply? Italian organizations with qualified principal investigators who can directly receive funding.

2. What is the maximum funding amount? €50,000 per project.

3. How long can a project last? Up to one year.

4. Are collaborations allowed? Yes, interdepartmental or interinstitutional collaborations are encouraged if roles are clearly defined.

5. Can projects focus on older patients or those with comorbidities? Yes, projects targeting these populations are highly relevant.

6. Should patient-reported outcomes be included? Yes, the grant prioritizes integrating tools that capture patients’ subjective treatment impact.

7. What types of projects are eligible? Quality improvement initiatives, research studies, personalized monitoring strategies, and interventions improving quality of care for HR+/HER2- metastatic breast cancer.

Conclusion

Pfizer’s grant program offers Italian organizations an opportunity to advance patient-centered care, improve quality of life, and implement research or quality improvement strategies for HR+/HER2- metastatic breast cancer. Projects focusing on clinical innovation, psychosocial support, and measurable improvements in patient care are highly encouraged. Careful planning, clear objectives, and a patient-centered approach are essential for a successful application.

For more information, visit Pfizer.